New Amsterdam Pharma is a technology company.
New Amsterdam Pharma has raised $190.0M across 1 funding round.
New Amsterdam Pharma has raised $190.0M in total across 1 funding round.
New Amsterdam Pharma has raised $190.0M in total across 1 funding round.
New Amsterdam Pharma's investors include Ascendant BioCapital, Forbion, Founders Fund, Presight Capital.
NewAmsterdam Pharma (Nasdaq: NAMS) is a clinical-stage biopharmaceutical company focused on developing innovative therapies for cardiovascular disease (CVD) and lipid-related conditions, primarily through its lead candidate obicetrapib, a novel CETP inhibitor designed to lower LDL-C and reduce cardiovascular risk.[1][2][3] The company serves patients with unmet needs in lipid management despite existing therapies, aiming to transform lipid-lowering treatments and prevent CVD, the leading global killer.[1][2] It has shown strong growth momentum, including a 2022 Nasdaq debut raising $328 million, a 2023 public offering netting $190 million, Phase 3 trial initiations, and positive topline Alzheimer's data from the BROADWAY trial in May 2025.[1]
NewAmsterdam Pharma was co-founded by renowned lipidologist Professor Dr. John Kastelein and venture capital firm Forbion, leveraging expertise in CVD and lipid science.[1][3] In January 2020, the company acquired all rights to obicetrapib from an Amgen subsidiary, marking its foundational step.[1] Key milestones include dosing the first patient in the Phase 3 BROOKLYN trial in June 2022, going public on Nasdaq in July 2022, presenting Phase 2 ROSE2 data in November 2022, appointing its first Chief Commercial Officer in June 2023, dosing the first patient in the TANDEM trial in February 2024, and announcing positive Alzheimer's data from BROADWAY in May-June 2025.[1]
NewAmsterdam rides the trend of precision medicine in cardiometabolic diseases, where genetic insights into CETP inform next-generation lipid therapies amid rising CVD prevalence.[1][2][3] Timing aligns with post-statin demands for oral, potent LDL-C reducers, especially as patents expire on legacy drugs, creating market gaps.[3] Favorable forces include robust investor support (e.g., $518 million raised via IPO and offerings) and expanding Phase 3 data, positioning it to influence biopharma's shift toward combo therapies and CVD prevention.[1][4] By exploring Alzheimer's links, it broadens impact into neurodegeneration, potentially reshaping multi-disease pipelines.[1]
NewAmsterdam is poised for pivotal readouts from ongoing Phase 3 trials like BROOKLYN and TANDEM, with commercial readiness underway and recent Alzheimer's data opening new avenues.[1][2] Trends in personalized CVD therapies, combo regimens, and AI-driven trial design will accelerate its path, potentially leading to approvals by 2026-2027 if data holds.[1] Its influence may grow as a lipid-lowering leader, enabling patients to control cardiovascular risk and live fuller lives—directly advancing its mission to redefine CVD treatment.[1][2]
New Amsterdam Pharma has raised $190.0M across 1 funding round. Most recently, it raised $190.0M Series A in January 2021.
| Date | Round | Lead Investors | Other Investors |
|---|---|---|---|
| Jan 1, 2021 | $190.0M Series A | Ascendant BioCapital, Forbion, Founders Fund, Presight Capital |